

## Literature curriculum for CCBIO906 Cancer Genomics Course, UIB 2023

### Core literature (~ 250 pages)

1. Cortés-Ciriano, I., Gulhan, D.C., Lee, J.J.K. et al. Computational analysis of cancer genome sequencing data. *Nat Rev Genet* (2021). <https://doi.org/10.1038/s41576-021-00431-y>
2. Li, Y., Roberts, N.D., Wala, J.A. et al. Patterns of somatic structural variation in human cancer genomes. *Nature* (2020). <https://doi.org/10.1038/s41586-019-1913-9>
3. McDermott U, Downing J, Stratton M. Genomics and the continuum of cancer care. *N Engl J Med* (2011). <http://dx.doi.org/10.1056/NEJMra0907178>
4. Biesecker LG, (null) RCG. Diagnostic Clinical Genome and Exome Sequencing. *New Engl J Med* (2014). <http://dx.doi.org/10.1056/NEJMra1312543>
5. Byron SA, Van Keuren-Jensen KR, Engelthaler DM, Carpten JD, Craig DW. Translating RNA sequencing into clinical diagnostics: opportunities and challenges. *Nat Rev Genet* (2016) <http://dx.doi.org/10.1038/nrg.2016.10>
6. Collisson EA, Cho RJ, Gray JW. What are we learning from the cancer genome? *Nat Rev Clin Oncol* (2012). <http://dx.doi.org/10.1038/nrclinonc.2012.159>
7. Lei Y, Tang R, Xu J, Wang W, Zhang B, Liu J, Yu X, Shi S. Applications of single-cell sequencing in cancer research: progress and perspectives. *J Hematol Oncol* (2021). <http://doi.org/10.1186/s13045-021-01105-2>
8. Hofree M, Carter H, Kreisberg JF, Bandyopadhyay S, Mischel PS, Friend S, et al. Challenges in identifying cancer genes by analysis of exome sequencing data. *Nat Commun.* (2016). <http://dx.doi.org/10.1038/ncomms12096>
9. Gerstung, M., Jolly, C., Leshchiner, I. et al. The evolutionary history of 2,658 cancers. *Nature* (2020). <https://doi.org/10.1038/s41586-019-1907-7>
10. Suwinski P, Ong C, Ling MHT, Poh YM, Khan AM, Ong HS. Advancing Personalized Medicine Through the Application of Whole Exome Sequencing and Big Data Analytics. *Front Genet* (2019). <http://doi.org/10.3389/fgene.2019.00049>
11. Berger MF, Mardis ER. The emerging clinical relevance of genomics in cancer medicine. *Nat Rev Clin Oncol* (2018). <http://doi.org/10.1038/s41571-018-0002-6>
12. Lawrence, R., Watters, M., Davies, C. R., Pantel, K., & Lu, Y. J. (2023). Circulating tumour cells for early detection of clinically relevant cancer. *Nature reviews. Clinical oncology*, 20(7), 487–500. <https://doi.org/10.1038/s41571-023-00781-y>
13. Seferbekova, Z., Lomakin, A., Yates, L. R., & Gerstung, M. (2023). Spatial biology of cancer evolution. *Nature reviews. Genetics*, 24(5), 295–313. <https://doi.org/10.1038/s41576-022-00553-x>
14. van de Merbel, A. F., van der Horst, G., & van der Pluijm, G. (2021). Patient-derived tumour models for personalized therapeutics in urological cancers. *Nature reviews. Urology*, 18(1), 33–45. <https://doi.org/10.1038/s41585-020-00389-2>
15. Aldea, M., Friboulet, L., et al. (2023). Precision medicine in the era of multi-omics: can the data tsunami guide rational treatment decision?. *ESMO open*, 8(5), <https://doi.org/10.1016/j.esmoop.2023.101642>

### Additional literature (~ 250 pages)

1. Alexandrov, L. B., Kim, J., Haradhvala, N. J., Huang, M. N., (...), PCAWG Consortium (2020). The repertoire of mutational signatures in human cancer. *Nature*, 578(7793), 94–101. <https://doi.org/10.1038/s41586-020-1943-3>
2. Van Allen EM, Wagle N, Stojanov P, Perrin DL, Cibulskis K, Marlow S, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-, embedded tumor samples to guide precision cancer medicine. *Nat Med.* (2014). <http://dx.doi.org/10.1038/nm.3559>

4. Gawad C, Koh W, Quake SR. Single-cell genome sequencing: current state of the science. *Nat Rev Genet* (2016). <http://dx.doi.org/10.1038/nrg.2015.16>
5. Griffith M, Spies NC, Krysiak K, McMichael JF, Coffman AC, Danos AM, et al. CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer. *Nat Genet* (2017). <http://dx.doi.org/10.1038/ng.3774>
6. Harris G, O'Toole S, George P, Browett P, Print C. Massive Parallel Sequencing of Solid Tumours - Challenges and Opportunities for Pathologists. *Histopathology* (2016). <http://dx.doi.org/10.1111/his.13067>
7. Kim E, Ilic N, Shrestha Y, Zou L, Kamburov A, Zhu C, et al. Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles. *Cancer Discovery* (2016). <http://dx.doi.org/10.1158/2159-8290.CD-16-0160>
8. Knoppers BM, Zawati MH, Sénécal K. Return of genetic testing results in the era of whole-genome sequencing. *Nat Rev Genet* (2015). <http://dx.doi.org/10.1038/nrg3960>
9. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al. VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing. *Genome Res* (2012). <http://dx.doi.org/10.1101/gr.129684.111>
10. Liu B, Conroy JM, Morrison CD, Odunsi AO, Qin M, Wei L, et al. Structural variation discovery in the cancer genome using next generation sequencing: computational solutions and perspectives. *Oncotarget* (2015). <http://dx.doi.org/10.18632/oncotarget.3491>
11. Kurnit KC, Dumbrava EEI, Litzenburger B, et al. Precision Oncology Decision Support: Current Approaches and Strategies for the Future. *Clin Cancer Res* (2018). <http://doi.org/10.1158/1078-0432.CCR-17-2494>
12. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. *Nat Rev Genet* (2010). <http://dx.doi.org/10.1038/nrg2841>
13. Nagarajan N, Pop M. Sequence assembly demystified. *Nat Rev Genet* (2013). <http://dx.doi.org/10.1038/nrg3367>
14. Shendure J, Aiden EL. The expanding scope of DNA sequencing. *Nat Biotechnol* (2012). <http://dx.doi.org/10.1038/nbt.2421>
15. Simonis M, Kooren J, de Laat W. An evaluation of 3C-based methods to capture DNA interactions. *Nat Meth* (2007). <http://dx.doi.org/10.1038/nmeth1114>
16. Yang L, Luquette LJ, Gehlenborg N, Xi R, Haseley PS. Diverse Mechanisms of Somatic Structural Variations in Human Cancer Genomes. *Cell* (2013). <http://dx.doi.org/10.1016/j.cell.2013.04.010>
17. Zhang X, Marjani SL, Hu Z, Weissman SM, Pan X, Wu S. Single-Cell Sequencing for Precise Cancer Research: Progress and Prospects. *Cancer Res* (2016). <http://dx.doi.org/10.1158/0008-5472.CAN-15-1907>
18. Borry P, Bentzen HB, Budin-Ljøsne I, Corne MC, Howard HC, Feeney O, et al. The challenges of the expanded availability of genomic information: an agenda-setting paper. *J Community Genet* (2018). <http://dx.doi.org/10.1007/s12687-017-0331-7>
19. Paczkowska, M., Barenboim, J., Sintupisut, N. et al. Integrative pathway enrichment analysis of multivariate omics data. *Nat Commun* (2020). <https://doi.org/10.1038/s41467-019-13983-9>
20. Lim B, Lin Y, Navin N. Advancing Cancer Research and Medicine with Single-Cell Genomics. *Cancer Cell* (2020). <http://doi.org/10.1016/j.ccell.2020.03.008>
21. Nature outlook, 25 March 2020. How cancer genomics is transforming diagnosis and treatment? <https://www.nature.com/articles/d41586-020-00845-4>
22. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature* (2012) <https://doi.org/10.1038/nature11003>